Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NVX-COV2373,Matrix-M
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Partnership
PolyPeptide Group Partners with Novavax on COVID-19 Vaccine
Details : PolyPeptide will produce 2 key intermediates used in the production of Matrix-M to enhance the vaccine’s immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : NVX-COV2373,Matrix-M
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
